CA
PCVX icon

Continuum Advisory’s Vaxcyte PCVX Stock Holding History

Continuum Advisory’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63
Closed -$2.38K – 1229
2025
Q1 		$2.38K Buy
63
+17
+37% +$1.36K ﹤0.01% 1295
2024
Q4 		$3.77K Sell
46
-46
-50% -$4.57K ﹤0.01% 1207
2024
Q3 		$8.53K Sell
92
-2
-2% -$180 ﹤0.01% 1040
2024
Q2 		$7.1K Sell
94
-6
-6% -$408 ﹤0.01% 1024
2024
Q1 		$6.56K Buy
+100
New +$6.92K ﹤0.01% 1026

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Continuum Advisory's PCVX Position: Q2 2025 in Review

Continuum Advisory sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 63 shares — an estimated $2.38K sold.

Continuum Advisory first reported a position in PCVX in Q1 2024 and held it in 5 quarters. The position peaked at $8.53K in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Continuum Advisory reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 63 Vaxcyte shares in Q2 2025, an estimated $2.38K.
  • Continuum Advisory first reported a position in Vaxcyte in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Vaxcyte position peaked at $8.53K in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.